Ann: Board Changes, page-17

First 17 Last

Share
Profile

Follow
Deme

1,484 Posts.

1308

13/04/23

14:20

Post #: 67257256
Share

Originally posted by Bison8: ↑

I'm not disagreeing with you about the BOD. Their abilities ran out of puff when it came to the all-important finance part of the project. The BOD did bring the project forward to the point of completed drilling, obtaining government permitting, refurbishing parts of the project, etc. Really the only failure here is the lack of finance and major issues from COVID lockdown policies which was the major wrecking ball with everything happing going into the downturn of the market.
Having said all that why the hell is copper still above $4/Lb if the economy is cooked and the banks are in crisis?
Yeah nah, it's not currently.
Employment is still strong with inflation going down. It's all about perception and people have been advocating a recession since June last year, many here calling we're all doomed last July with recession a killer. It's now mid April 2023.
I'd be happy to see Barry step down a ladder but stay on the BOD to build the project. He has obvious talents in non finance-related aspects. Obtain some real know-how with experts to get the finance happening which is what this needed last year. I mean where were the multiple parties to negotiate finance deals with, instead of relying on 1 at a time BS. Glencore wrecked this with 6 months of exclusivity and the BOD never reacted. At least not publicly.

Expand

Which is pretty much what I have been saying since the bond debacle & subsequent events.

Access to capital is everything in this game. Narratives mean squat without it.

Bring in "financiers", move Baz to a technical ops role (if he wants) & let's get this show on the road.

CYM Price at posting: 11.0¢ Sentiment: Hold Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

There are more pages in this discussion • 51 more messages in this thread...

First 17 Last

Add CYM (ASX) to my watchlist

(20min delay)
Last 3.3¢		Change 0.000(0.00%)		Mkt cap ! $50.35M

Open	High	Low	Value	Volume
3.4¢	3.5¢	3.2¢	$26.94K	806.9K

Buyers (Bids)

No.	Vol.	Price($)
2	126221	3.2¢

Sellers (Offers)

Price($)	Vol.	No.
3.4¢	300000	1

View Market Depth

No.	Vol.	Price($)
2	126221	0.032
4	333300	0.030
3	533248	0.029
2	532061	0.028
4	3138062	0.027

Price($)	Vol.	No.
0.034	300000	1
0.035	70620	1
0.036	289495	2
0.037	474254	3
0.038	421845	2

Last trade - 15.32pm 07/10/2024 (20 minute delay)

CYM (ASX) Chart

Ann: Board Changes, page-17

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Board Changes, page-17

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News